A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 23 Sep 2019
Price : $35 *
At a glance
- Drugs Trametinib (Primary) ; Uprosertib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 27 Aug 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 03 Mar 2017 Status changed from recruiting to active, no longer recruiting.